Andrew Hughes

Biography

Professor Andrew Hughes leads the experimental cancer medicine team at The Christie. This role involves overseeing the clinical contribution to Phase 1 cancer clinical trials and a strategic growth of the research by up to 10 fold over the next 5 years. Previous to that Andrew was Global VP of early clinical development at AstraZeneca Pharmaceuticals leading over 50 research and early clinical development programmes of novel candidate drugs. He graduated with double first in medical sciences at Cambridge, spending 3 years as a Tutor in Physiology and Bye-fellow of Downing College, Cambridge, whilst completing a PhD in behavioural neuroendocrinology in the Department of Anatomy. He subsequently practised general clinical medicine in Manchester’s teaching hospitals in the UK, joining Zeneca in 1994 from being a registrar in Cardiology, and until recently continued with clinical work. Within the industry, he has had responsibilities on the corporate pain control drug development board and in setting the limits of human exposure based on existing pre-clinical and clinical data for all development products. Since 2001 he has been accountable for the early phase clinical development of AstraZeneca’s oncology compounds in volunteers and patients, and has been clinical investigator on over 200 clinical trials. He is approved by the Resuscitation Council (UK) as a director in Advanced Cardiac Life Support, and regularly teaches health professionals in ACLS. During 2002-3 he served on the board of the Faculty of Pharmaceutical Medicine, UK; and has the responsibility for the clinical pharmacology revision module for those physicians sitting the Diploma of Pharmaceutical Medicine.

Research Interest

Experimental Cancer Medicine